Cite
HARVARD Citation
Irving, P. et al. (n.d.). DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn's Disease: Post-hoc analysis from the phase 3 study FORTIFY. Journal of Crohn's and colitis. pp. i127-i128. [Online].